Schizophrenia bulletin open最新文献

{"title":"Intranasal Oxytocin Combined With Social Skills Training for Schizophrenia: An Add-on Randomized Controlled Trial.","authors":"Liron Saporta-Wiesel, Ruth Feldman, Linda Levi, Michael Davidson, Shimon Burshtein, Ruben Gur, Orna Zagoory-Sharon, Revital Amiaz, Jinyoung Park, John M Davis, Mark Weiser","doi":"10.1093/schizbullopen/sgae022","DOIUrl":"10.1093/schizbullopen/sgae022","url":null,"abstract":"<p><p>Some but not other studies on oxytocin for schizophrenia, particularly those using a higher dose, indicate that oxytocin improves negative symptoms of schizophrenia. We performed an add-on randomized controlled trial to examine the effect of high-dose oxytocin, social skills training, and their combination in the treatment of negative symptoms and social dysfunction in schizophrenia. Fifty-one subjects with schizophrenia were randomized, employing a two-by-two design: intranasal oxytocin (24 IU X3/day) or placebo, and social skills training or supportive psychotherapy, for 3 weeks. The primary outcome was the difference in the total score from baseline to end-of-study of a semi-structured interview which assessed patients' social interactions in 3 scenarios: sharing a positive experience, sharing a conflict, and giving support when the experimenter shared a conflict. The interactions were scored using the Coding Interactive Behavior Manual (CIB), clinical symptoms were assessed with the Positive and Negative Syndrome Scale (PANSS). No significant difference was found between groups in the total CIB or PANSS scores. The majority of comparisons in the different social interactions between oxytocin and placebo, and between social skills training vs supportive psychotherapy, were also nonsignificant. Social skills training reduced blunted affect and gaze. In post-hoc analyses of the support interaction, oxytocin improved synchrony and decreased tension, while in the positive interaction it improved positive affect and avoidance. None of these findings remained significant when controlling for multiple comparisons. In conclusion, oxytocin did not influence participants' social behavior, and was not effective in improving the symptoms of schizophrenia. Clinicaltrials.gov Identifier: NCT01598623.</p>","PeriodicalId":94380,"journal":{"name":"Schizophrenia bulletin open","volume":"5 1","pages":"sgae022"},"PeriodicalIF":0.0,"publicationDate":"2024-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11535855/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142585331","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rationale and Challenges for a New Instrument for Remote Measurement of Negative Symptoms.","authors":"David Gordon Daniel, Alex S Cohen, Philip D Harvey, Dawn I Velligan, William Z Potter, William P Horan, Raeanne C Moore, Stephen R Marder","doi":"10.1093/schizbullopen/sgae027","DOIUrl":"10.1093/schizbullopen/sgae027","url":null,"abstract":"<p><p>There is a broad consensus that the commonly used clinician-administered rating scales for assessment of negative symptoms share significant limitations, including (1) reliance upon accurate self-report and recall from the patient and caregiver; (2) potential for sampling bias and thus being unrepresentative of daily-life experiences; (3) subjectivity of the symptom scoring process and limited sensitivity to change. These limitations led a work group from the International Society of CNS Clinical Trials and Methodology (ISCTM) to initiate the development of a multimodal negative symptom instrument. Experts from academia and industry reviewed the current methods of assessing the domains of negative symptoms including diminished (1) affect; (2) sociality; (3) verbal communication; (4) goal-directed behavior; and (5) Hedonic drives. For each domain, they documented the limitations of the current methods and recommended new approaches that could potentially be included in a multimodal instrument. The recommended methods for assessing negative symptoms included ecological momentary assessment (EMA), in which the patient self-reports their condition upon receipt of periodic prompts from a smartphone or other device during their daily routine; and direct inference of negative symptoms through detection and analysis of the patient's voice, appearance or activity from audio/visual or sensor-based (eg, global positioning systems, actigraphy) recordings captured by the patient's smartphone or other device. The process for developing an instrument could resemble the NIMH MATRICS process that was used to develop a battery for measuring cognition in schizophrenia. Although the EMA and other digital measures for negative symptoms are at relatively early stages of development/maturity and development of such an instrument faces substantial challenges, none of them are insurmountable.</p>","PeriodicalId":94380,"journal":{"name":"Schizophrenia bulletin open","volume":"5 1","pages":"sgae027"},"PeriodicalIF":0.0,"publicationDate":"2024-10-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11535854/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142585333","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cognitive Impairment Associated With Schizophrenia: New Research Agenda.","authors":"Silvana Galderisi, Stephen R Marder","doi":"10.1093/schizbullopen/sgae023","DOIUrl":"https://doi.org/10.1093/schizbullopen/sgae023","url":null,"abstract":"","PeriodicalId":94380,"journal":{"name":"Schizophrenia bulletin open","volume":"5 1","pages":"sgae023"},"PeriodicalIF":0.0,"publicationDate":"2024-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11457370/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142396590","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Negative Symptoms and Their Associations With Other Clinical Variables and Working Memory Across the Schizophrenia Spectrum and Bipolar Disorder.","authors":"Marco De Pieri, Xaver Berg, Foivos Georgiadis, Janis Brakowski, Achim Burrer, Michel Sabé, Mariia Kaliuzhna, Stefan Vetter, Erich Seifritz, Philipp Homan, Stefan Kaiser, Matthias Kirschner","doi":"10.1093/schizbullopen/sgae024","DOIUrl":"10.1093/schizbullopen/sgae024","url":null,"abstract":"<p><p>Negative symptoms (NS) of schizophrenia spectrum disorders (SSD) are also prevalent in bipolar disorder I (BD-I) and show associations with impaired working memory (WM). However, empirical work on their relationship to other clinical factors across SSD and BD-I is sparse. Here, we characterized the associations of NS with key clinical variables and WM capacity across a combined sample of SSD and BD. We included 50 outpatients with SSD and 49 with BD-I and assessed NS domains using SANS global scores for avolition-apathy, anhedonia-asociality, alogia, and blunted affect. We assessed the transdiagnostic relationship between NS and other clinical variables, including positive symptoms, disorganization, depressive symptoms, and antipsychotic medication, using multiple regressions. The strength of these associations was further determined through dominance analyses. Finally, we used multiple regression to assess the relationship between NS domains and WM. To assess the generalizability of transdiagnostic associations, analyses were repeated in each diagnostic group separately. Across SSD and BD-I, disorganization was associated with avolition-apathy and anhedonia-asociality and depressive symptoms additionally predicted anhedonia-asociality. Antipsychotic dose was associated with blunted affect while group differences only predicted alogia. Higher avolition-apathy was related to impaired WM transdiagnostically, partially mediated by the severity of disorganization, whereas only in BD-I higher anhedonia-asociality was associated with better WM capacity. This study demonstrated transdiagnostic associations of both avolition-apathy and anhedonia-asociality with disorganization and identified avolition-apathy as a potential transdiagnostic predictor of WM impairments. Overall, our findings highlight the importance of understanding the relationship between NS domains and other clinical factors with cognitive function across SSD and BD.</p>","PeriodicalId":94380,"journal":{"name":"Schizophrenia bulletin open","volume":"5 1","pages":"sgae024"},"PeriodicalIF":0.0,"publicationDate":"2024-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11487101/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142485035","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association Between Juvenile Psychotic Experiences and Problematic Gaming.","authors":"André Fernandes, Renan M Biokino, Andrew C C Miguel, Viviane Machado, Gabriela Koga, Laís Fonseca, Pedro M Pan, Thiago Henrique Roza, Giovanni Salum, Ives Cavalcante Passos, Luis Augusto Rohde, Euripedes Constantino Miguel, Carolina Ziebold, Ary Gadelha","doi":"10.1093/schizbullopen/sgae021","DOIUrl":"https://doi.org/10.1093/schizbullopen/sgae021","url":null,"abstract":"<p><strong>Background and hypothesis: </strong>Problematic gaming (PG) is an emerging mental health condition associated with significant adverse outcomes. Even though PG has been linked to other psychiatric disorders, its association with psychotic experiences (PEs) remains poorly explored to date. The aim of our study was to examine the association between both conditions in a large Brazilian community sample. We hypothesized that adolescents with PG were more likely to report PE compared with those without the disorder.</p><p><strong>Study design: </strong>Our investigation was based on a cross-sectional subsample of a large Brazilian cohort (<i>n</i> = 1616; 13- to 21-year age range). Using the 7-item version of the Game Addiction Scale, participants were classified according to their gaming status: no PG, PG, or gaming addiction (GA). The association between PG, GA, and PE was assessed through linear regression analyses, which were adjusted for the presence of significant covariates, including other psychiatric conditions.</p><p><strong>Study results: </strong>9.5% (<i>n</i> = 154) presented PG and 2.7% (<i>n</i> = 43) had GA. 28.0% received any <i>Diagnostic and Statistical Manual of Mental Disorders</i>, Fourth Edition (DSM-IV) diagnosis and the mean PE score was 9.39 (<i>SD</i> = 4.35). Participants presenting PG had greater levels of PE, compared with participants with no PG, even controlled by sociodemographic variables and the presence of any DSM-IV diagnosis (<i>b</i> = 0.96, 95% CI = 0.17-1.75, <i>P</i> = .017).</p><p><strong>Conclusions: </strong>According to our results, PG was significantly associated with PE, even in the presence of other covariates. Although preliminary, these results suggest that PG and PE may have shared neurobiological and/or behavioral pathways.</p>","PeriodicalId":94380,"journal":{"name":"Schizophrenia bulletin open","volume":"5 1","pages":"sgae021"},"PeriodicalIF":0.0,"publicationDate":"2024-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11408271/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142305497","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Biomarkers for Psychosis: Are We There Yet? Umbrella Review of 1478 Biomarkers.","authors":"Paola Fuentes-Claramonte, Andrés Estradé, Aleix Solanes, Valentina Ramella-Cravaro, Maria Angeles Garcia-Leon, Javier de Diego-Adeliño, Conrad Molins, Eric Fung, Marc Valentí, Gerard Anmella, Edith Pomarol-Clotet, Dominic Oliver, Eduard Vieta, Joaquim Radua, Paolo Fusar-Poli","doi":"10.1093/schizbullopen/sgae018","DOIUrl":"10.1093/schizbullopen/sgae018","url":null,"abstract":"<p><strong>Background and hypothesis: </strong>This umbrella review aims to comprehensively synthesize the evidence of association between peripheral, electrophysiological, neuroimaging, neuropathological, and other biomarkers and diagnosis of psychotic disorders.</p><p><strong>Study design: </strong>We selected systematic reviews and meta-analyses of observational studies on diagnostic biomarkers for psychotic disorders, published until February 1, 2018. Data extraction was conducted according to the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) guidelines. Evidence of association between biomarkers and psychotic disorders was classified as convincing, highly suggestive, suggestive, weak, or non-significant, using a standardized classification. Quality analyses used the Assessment of Multiple Systematic Reviews (AMSTAR) tool.</p><p><strong>Study results: </strong>The umbrella review included 110 meta-analyses or systematic reviews corresponding to 3892 individual studies, 1478 biomarkers, and 392 210 participants. No factor showed a convincing level of evidence. Highly suggestive evidence was observed for transglutaminase autoantibodies levels (odds ratio [OR] = 7.32; 95% CI: 3.36, 15.94), mismatch negativity in auditory event-related potentials (standardized mean difference [SMD] = 0.73; 95% CI: 0.5, 0.96), P300 component latency (SMD = -0.6; 95% CI: -0.83, -0.38), ventricle-brain ratio (SMD = 0.61; 95% CI: 0.5, 0.71), and minor physical anomalies (SMD = 0.99; 95% CI: 0.64, 1.34). Suggestive evidence was observed for folate, malondialdehyde, brain-derived neurotrophic factor, homocysteine, P50 sensory gating (P50 S2/S1 ratio), frontal <i>N</i>-acetyl-aspartate, and high-frequency heart rate variability. Among the remaining biomarkers, weak evidence was found for 626 and a non-significant association for 833 factors.</p><p><strong>Conclusions: </strong>While several biomarkers present highly suggestive or suggestive evidence of association with psychotic disorders, methodological biases, and underpowered studies call for future higher-quality research.</p>","PeriodicalId":94380,"journal":{"name":"Schizophrenia bulletin open","volume":"5 1","pages":"sgae018"},"PeriodicalIF":0.0,"publicationDate":"2024-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11369642/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142127812","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Racial and Ethnic Disparities in the Diagnosis and Early Treatment of First-Episode Psychosis.","authors":"Aubrey M Moe, Elyse Llamocca, Heather M Wastler, Danielle L Steelesmith, Guy Brock, Oladunni Oluwoye, Cynthia A Fontanella","doi":"10.1093/schizbullopen/sgae019","DOIUrl":"https://doi.org/10.1093/schizbullopen/sgae019","url":null,"abstract":"<p><strong>Background: </strong>Despite recognition that early intervention for first-episode psychosis (FEP) improves outcomes, Black youth with FEP continue to experience critical disparities in care. A historical lack of scientific focus on racial and ethnic factors in the study of psychosis and scant investigations among publicly insured (ie, Medicaid-enrolled) youth hinder our ability to understand and address factors that contribute to disparities in early FEP care. Strategies for improving FEP services for Black youth are reliant on more precise identification of <i>who</i> faces disparities and <i>when</i> during the early course of illness disparities are experienced.</p><p><strong>Study design: </strong>A retrospective longitudinal analysis of Ohio Medicaid claims data was performed for 987 982 youth aged 15-24 years between 2010 and 2020 to examine: (1) the likelihood of FEP diagnosis, (2) the type of psychotic disorder diagnosis received, and (3) receipt of treatment following psychosis onset.</p><p><strong>Study results: </strong>Non-Hispanic Black (NHB) youth, relative to non-Hispanic White (NHW) peers, were more likely to be diagnosed with a psychotic disorder and were further more likely to receive a diagnosis of schizophrenia relative to an affective psychotic disorder. In the first year following FEP diagnosis, NHB youth were also less likely to receive psychotherapy than NHW youth; this disparity was no longer present when examined at 2 years following FEP.</p><p><strong>Conclusions: </strong>In this study, Black youth experienced disparities in both the diagnosis and early treatment of FEP. Additional efforts are needed to understand and address these observed disparities and to promote equitable access to FEP care during the critical early illness phases.</p>","PeriodicalId":94380,"journal":{"name":"Schizophrenia bulletin open","volume":"5 1","pages":"sgae019"},"PeriodicalIF":0.0,"publicationDate":"2024-08-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11350282/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142116812","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Interview Versus Performance Assessment of Cognition as Predictors of Real-World Outcomes in a Large-Scale Cross-Sectional Study in Schizophrenia.","authors":"Pasquale Pezzella, Edoardo Caporusso, Armida Mucci, Paola Bucci, Giulia M Giordano, Mario Amore, Paola Rocca, Alessandro Rossi, Alessandro Bertolino, Joseph Ventura, Silvana Galderisi, Mario Maj","doi":"10.1093/schizbullopen/sgae020","DOIUrl":"10.1093/schizbullopen/sgae020","url":null,"abstract":"<p><p>The Cognitive Assessment Interview (CAI) is an interview-based scale measuring cognitive impairment and its impact on functioning in subjects with schizophrenia (SCZ). It is approved as a coprimary measure of performance-based instruments, such as the Measurement and Treatment Research to Improve Cognition in Schizophrenia Consensus Cognitive Battery (MCCB). Recent research highlights negative symptoms, social cognition, and functional capacity as mediators of cognitive impairment's impact on functioning. This study compared mediation analysis outcomes using CAI or MCCB scores, providing insights into the utility of interview-based tools in research and clinical practice. The study included 618 individuals diagnosed with schizophrenia, recruited from 24 Italian psychiatric clinics. Neurocognitive assessments utilized both CAI and MCCB. Mediation analyses explored negative symptoms, social cognition, and functional capacity as mediators of the impact of neurocognition on real-life functioning domains. The study's results extend the validation of the CAI as a coprimary measure that provides valid information on the impact of cognitive impairment on real-life functioning and its possible mediators, complementing the information obtained using the MCCB. Interview-based cognitive assessment might be essential for understanding schizophrenia complexity and its impact on various cognitive and functional domains for clinicians, patients, and caregivers.</p>","PeriodicalId":94380,"journal":{"name":"Schizophrenia bulletin open","volume":"5 1","pages":"sgae020"},"PeriodicalIF":0.0,"publicationDate":"2024-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11362673/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142116805","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Tale of three spectra: Basic symptoms in clinical high risk of psychosis vary across autism spectrum disorder, schizotypal personality disorder, and borderline personality disorder","authors":"James C Martin, Scott R. Clark, Simon Hartmann, K. O. Schubert","doi":"10.1093/schizbullopen/sgae017","DOIUrl":"https://doi.org/10.1093/schizbullopen/sgae017","url":null,"abstract":"\u0000 \u0000 \u0000 The clinical-high-risk (CHR) approach was developed to prevent psychosis through the detection of psychosis-risk. CHR services are transdiagnostic in nature, therefore the appropriate management of comorbidity is a central part of care. Differential diagnosis is particularly challenging across three common comorbidities, schizotypal personality disorder (SPD), autism spectrum disorder (ASD), and borderline personality disorder (BPD). Phenomenological research indicates a disturbance of ‘basic self’ may differentiate between these commonly comorbid disorders and can be captured by Huber’s basic symptoms (BS) concept. We investigated whether BS vary across these disorders and may inform differential diagnosis in young person’s meeting CHR criteria.\u0000 \u0000 \u0000 \u0000 685 participants meeting CHR criteria from the NAPLS-3 cohort completed the COGDIS items of the schizophrenia proneness instrument, a measure of BS, as well as the structured interview for DSM-5 (SCID-5). A Logistic regression model was used to investigate the variation of COGDIS across SPD, ASD, and BPD, whilst controlling for age and SIPs positive severity.\u0000 \u0000 \u0000 \u0000 Meeting COGDIS criteria was positively associated with SPD (OR = 1.72, CI=[1.31-2.28], p=0.001) but not ASD nor BPD.\u0000 \u0000 \u0000 \u0000 Our results indicate that ‘basic self-disturbance’ as indicated by COGDIS differs across SPD, ASD, and BPD. COGDIS may be useful to inform the management of comorbidities in CHR services, by providing insight into subtle subjective experiences that may benefit from disorder-specific interventions.\u0000","PeriodicalId":94380,"journal":{"name":"Schizophrenia bulletin open","volume":"86 20","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-07-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141797945","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Using Task-fMRI to Explore the Relationship Between Lifetime Cannabis Use and Cognitive Control in Individuals with First Episode Schizophrenia","authors":"T. Lesh, Joshua P Rhilinger, Rylee Brower, Alex M. Mawla, J. Ragland, T. Niendam, C. S. Carter","doi":"10.1093/schizbullopen/sgae016","DOIUrl":"https://doi.org/10.1093/schizbullopen/sgae016","url":null,"abstract":"\u0000 While continued cannabis use and misuse in individuals with schizophrenia is associated with a variety of negative outcomes, individuals with a history of use tend to show higher cognitive performance compared to non-users. While this is replicated in the literature, few studies have used task-based functional magnetic resonance imaging (fMRI) to evaluate whether the brain networks underpinning these cognitive features are similarly impacted. Forty-eight first episode individuals with schizophrenia (FES) with a history of cannabis use (FES+CAN), 28 FES individuals with no history of cannabis use (FES-CAN), and 59 controls (CON) performed the AX-Continuous Performance Task during fMRI. FES+CAN showed higher cognitive control performance (d’-context) compared to FES-CAN (p<.05, ηp2=.053), and both FES+CAN (p<.05, ηp2=.049) and FES-CAN (p<.001, ηp2=.216) showed lower performance compared to CON. FES+CAN (p<.05, ηp2=.055) and CON (p<.05, ηp2=.058) showed higher dorsolateral prefrontal cortex (DLPFC) activation during the task compared to FES-CAN, while FES+CAN and CON were not significantly different. Within the FES+CAN group, younger age of initiation of cannabis use was associated with lower IQ and lower global functioning. More frequent use was also associated with higher reality distortion symptoms at the time of the scan. These data are consistent with previous literature suggesting that individuals with schizophrenia and a history of cannabis use have higher cognitive control performance. For the first time, we also reveal that FES+CAN have higher DLPFC brain activity during cognitive control compared to FES-CAN. Several possible explanations for these findings are discussed.","PeriodicalId":94380,"journal":{"name":"Schizophrenia bulletin open","volume":"69 15","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141806661","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}